drugset / Trial / NCT01692925

Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A

NCT01692925

Phase 1 Completed 15 enrolled Novo Nordisk A/S
RandomizedCrossoverOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body) of four lots of turoctocog alfa (a human recombinant coagulation factor VIII (FVIII)) in subjects with haemophilia A.

Timeline

Start
2012-12
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject turoctocog alfa Protein / enzyme biologic 2000 iu Intravenous
Subject turoctocog alfa Protein / enzyme biologic 3000 iu Intravenous

Indications